| 000 | 01682 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250516200241.0 | ||
| 264 | 0 | _c20141118 | |
| 008 | 201411s 0 0 eng d | ||
| 022 | _a1665-2681 | ||
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aD'heygere, François | |
| 245 | 0 | 0 |
_aSVR24 rates in patients with HCV genotype 5 and 6 infection treated with peginterferon alfa-2a (40KD) plus ribavirin: results from the real world PROPHESYS study. _h[electronic resource] |
| 260 |
_bAnnals of hepatology _c |
||
| 300 |
_a303-4 p. _bdigital |
||
| 500 | _aPublication Type: Letter; Multicenter Study; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAntiviral Agents _xtherapeutic use |
| 650 | 0 | 4 | _aCohort Studies |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aGenotype |
| 650 | 0 | 4 |
_aHepacivirus _xgenetics |
| 650 | 0 | 4 |
_aHepatitis C _xblood |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aInterferon-alpha _xtherapeutic use |
| 650 | 0 | 4 | _aInternational Cooperation |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aPolyethylene Glycols _xtherapeutic use |
| 650 | 0 | 4 | _aPragmatic Clinical Trials as Topic |
| 650 | 0 | 4 |
_aRNA, Viral _xblood |
| 650 | 0 | 4 |
_aRecombinant Proteins _xtherapeutic use |
| 650 | 0 | 4 |
_aRibavirin _xtherapeutic use |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 | _aViral Load |
| 700 | 1 | _aGeorge, Christophe | |
| 700 | 1 | _aHabersetzer, François | |
| 700 | 1 | _aTripathi, Davender | |
| 700 | 1 | _aQ Pan, Calvin | |
| 700 | 1 | _aGiron, Jose A | |
| 700 | 1 | _aSchmitz, Manuela | |
| 700 | 1 | _aTatsch, Fernando | |
| 773 | 0 |
_tAnnals of hepatology _gvol. 13 _gno. 2 _gp. 303-4 |
|
| 999 |
_c23575250 _d23575250 |
||